Hospital General Universitario Gregorio Maranon, Surgery, Madrid, Spain 3 Hospital General Universitario Gregorio Maranon, Radiation Oncology, Madrid, Spain Purpose or Objective: To evaluate the contribution of components for intense multimodal local treatment to the most adverse loco-regional staging scenario of M0 rectal cancer.
Material and Methods:
From 1/00 to 12/13, 95 cT4NXM0 patients were treated with radical intent. 54 completed preoperative intensified chemo-radiation (all had postresection intraoperative electron pelvic boost, IOERT). Adjuvant systemic chemotherapy was recommended considering individualized risk features. Incomplete and complete pre and intra-operative treatment cohorts were comparable in characteristics: male (44/55%); age >70 (44/33%); PS 0 (46/62%); inferior segment (42/41%); grade 2 (67/62%); cN+ (75/83%).
Results:
With a median follow-up time of 62 months overall, disease-free (DFS) and loco-regional relapse-free survival were superior in the cohort of complete intensification (75% vs 51%, p= 0.009; 67% vs 54%, p= 0.03; 77% vs 71%, p= 0.01), respectively. IOERT significantly improved presacral control rates. Multivariate analysis indicated that uninvolved surgical margin and intense tumour regression grade assessed response, were protective for DFS.
Conclusion:
Multimodal preoperative approach contributed to remarkable cancer-control outcomes and survival in cT4M0 rectal patients, if components of therapy are feasible to be maximized (including free surgical margins) and an intense pathological disease response is described. 
EP-1302

Material and Methods:
This is a retrospective analysis of 28 patients in whom SCCAg serum level was increased prior to treatment (mean 6,4 ng/ml, range 1,6-19,6 ng/ml). In all patients, measurement of SCCAg was performed at baseline, after completion of chemoradiation and at each visit during follow-up (median 35 months, range 7-81). All patients were treated radically.
Results: In 27 (96%) patients SCCAg level decreased to normal level after treatment. One remaining patient had persistent unreseceble tumor confirmed by pathology and persistent high SCCAg level. Only one of 27 patients with normalization of SCCAg after chemoradiation had persistent ulceration in the anal canal and persistent enlarger inguinal lymph node. This patient underwent abdominoperineal resection with inguinal lymphadenectomy. On pathological examination only a few cancer cells were found in the inguinal nodes and the primary tumour site was free of cancer.. In six patients, increase of SCCAg was observed during follow-up. In one of these 6 patients, locoregional recurrence was also detected clinically at the same time. In 4 patients, the diagnostic examinations performed because of elevated SCCAg reveled locoregional recurrence (n=2) or distant metastases (n=2). In one remaining patient the diagnostic examinations were negative; distant metastases were detected 5 months thereafter. The remaining 20 patients had both: sustained clinical complete regression and normal SCCAg level. to total mesorectum and pelvic lymphatic drainage with simultaneous integrated boost (SIB) to the tumor bed and adjacent mesorectum. Fluoropirimidine-based CT was administered. The acute toxicity was evaluated according to CTCAE 4.0 scale.
Conclusion
Results: Pts characteristics: median age 63.5yy (range 29-84), median tumor distance-IAS 50 mm (range 0-100), median tumor size 50 mm (range 25-120), MRF involvement 24 pts, Stage IIA 7 pts -III 62 pts. All of the pts completed the RT; 45 Gy were delivered to total mesorectum and lymphatic drainage with median SIB dose of 55 Gy (range 52.5-57.5). Forty-nine (71%) pts received concomitant CT with capecitabine alone and 17 (25%) capecitabine plus oxaliplatin. Globally, 16/69 (23%) pts did not complete CT for haematological (5) or, gastrointestinal toxicities (5) and other causes (6). Fourteen (20%), 33 (48%) and 23 (33%) pts experienced grade 1-2 haematological, gastrointestinal and genitourinary toxicity, respectively. Two out of 69 (3%) pts developed grade 3 haematological toxicity and 9/69 (13%) grade 3 gastrointestinal toxicity. Forty-three pts underwent surgery (LAR 28, APR 10, local excision 5 pts) but definitive histology is not yet available in 7 pts. Twenty-six pts are waiting for surgery. The tumor downstaging was documented in 29/36 (80.5%) pts. Forty-four rate (16/36) of surgical cases achieved pathologic complete response.
Conclusion:
Despite the limitations related to the heterogeneity of the treatment delivery (SIB dose and concomitant CT), the RT dose-escalation in the preoperative treatment of LARC seems feasible, well tolerated and effective in terms of tumor downstaging and pathological complete response. Nevertheless, this results need to be confirmed on a larger cohort.
EP-1304
Image guided intensity modulated radiotherapy for anal cancer: a multi institutional study B. De Bari 
Material and Methods:
Local control (LC) and grade 3 or more toxicity rate (CTCAE v.4.0) were the primary endpoints. Overall (OS), disease-free (DFS), distant metastasis-free (DMFS) and colostomy-free survival (CFS) were also studied. Volumes were defined as follows: CTV1 : Anal canal, mesorectal, pelvic, and inguinal nodes. CTV2 : anal tumor and clinically positive nodes. Planning target volumes were obtained by adding 5-mm margin to the CTV (PTV1 and PTV2, respectively). PTV1 received 36 Gy (1.8 Gy/fraction) delivered with IMRT (n = 44), VMAT (n = 16) or HT (n = 100), while PTV2 received a sequential boost up to a total dose of 59.4-60 Gy (1.8-2 Gy/fr), delivered with IMRT (n = 16), VMAT (n = 18) , HT (n = 59) or 3D-conformal RT (CRT, n = 67).
Results: From 03.2006 to 04.2015, 160 patients were treated; 30, 68, 60 and 2 patients presented stage I, II, III, and IV, respectively. Median age was 62 years (range: 35-89). A planned gap was used in 130 patients. Median gap duration was 10 days (range, 5-24) . Concomitant chemotherapy (CTX) was delivered in 149 patients, mainly using mitomycine C combined with fluoropyrimidines (i.v. or oral, n = 139). Median follow-up was 45 months (range: 3-97). Four-year LC, OS, DFS, DMFS and CFS rates were 83.6%, 82.3%, 82.7%, 93.4% and 88%, respectively. Time to progression for relapsing patients was 29 months (range: 1-78). A total of 24 patients presented a recurrence (local only in 14, locoregional in 1, locoregional and distant in 1, local and distant in 3, regional only in 2, and distant only in 3 patients). Fourteen patients underwent a colostomy because of local recurrence (n = 12) or pretreatment anal sphincter dysfunction (n = 2). Grade 3 acute toxicity was observed in 30 patients (18.4%), usually as erythema (23/30) or diarrhoea (10/30). No late G3 cutaneous toxicity was recorded. At the time of analysis, 150 patients presented more than 6 months of follow-up and were considered evaluable for late toxicity. Data about late toxicity were not available for 6 patients, followed in other Institutions. Looking at the final 144 patients, 3 of them patients presented a late G3 gastrointestinal toxicity (anal incontinence). No G4 acute or late toxicity was recorded. No significant differences were observed in terms of local control or acute G3 toxicity between IMRT and 3D-CRT boost techniques.
